BioSpecifics Technologies Corporation
35 Wilbur Street
218 articles with BioSpecifics Technologies Corporation
BioSpecifics Technologies Corp. announced its financial results for the first quarter ended March 31, 2019 and provided a corporate update.
Positive data from Phase 1 trial of CCH for treatment of uterine fibroids presented at 66th Annual Meeting of the Society for Reproductive Investigation in March 2019
Mr. Wegman served as an officer at BioSpecifics for over 20 years and was a member of the Board of Directors since 1994.
BioSpecifics Technologies Corp. Appoints Ron Law, Ph.D, J.D., as Senior Vice President of Business Development
BioSpecifics Technologies Corp. today announced that Ron Law, Ph.D., J.D. has been appointed as Senior Vice President of Business Development and will be responsible for strategic partnerships, reporting directly to Thomas L. Wegman, President of BioSpecifics. Dr. Law has been consulting for BioSpecifics since July 15, 2018.
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced its financial results for the third quarter ended September 30, 2018 and provided a corporate updat
BioSpecifics Technologies Corp. Announces Positive Topline Results from Phase 1 Study of CCH for the Treatment of Uterine Fibroids
BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company that originated and continues to develop collagenase-based therapies with a first in class collagenase-based product marketed as XIAFLEX® in the U.S. and Xiapex® in Europe, today announced positive topline data from its Phase 1 trial of Collagenase Clostridium Histolyticum
BioSpecifics Technologies Corp. today announced that BioSpecifics' President, Tom Wegman, will present a corporate overview at the following upcoming conferences in September.
Phase 1 trial of CCH for treatment of Uterine fibroids now fully enrolled
Continued year-over-year revenue growth for XIAFLEX
BioSpecifics reported net income of $2.6 million for the fourth quarter ended December 31, 2017.
Total revenue for the third quarter ended September 30, 2017 was $6.5M compared to $6.9M for the same period in 2016.
BioSpecifics Technologies Corporation Initiates Phase I Clinical Trial Of XIAFLEX For Treatment Of Uterine Fibroids
BioSpecifics Technologies Corporation Announces Positive Data From Phase 2b Study Of CCH In Patients With Cellulite
BioSpecifics Technologies Corporation To Report Third Quarter 2016 Financial Results On Wednesday, November 9, 2016